Evotec stock advances as BMS partnership wins second FDA IND acceptance
Published on 11/19/2026 at 12:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec advances partnered drug pipeline
- The FDA accepted a second IND application from Evotec's strategic protein degradation partnership with Bristol Myers Squibb.
- The CELMoD candidate is expected to enter a Phase 1 clinical trial in 2027.
- The partnership's first candidate entered Phase 1 testing in advanced clear cell renal cell carcinoma in March 2026.
Evotec said on Thursday, November 19, 2026, that the U.S. Food and Drug Administration accepted a second Investigational New Drug application from its strategic protein degradation partnership with Bristol Myers Squibb. The company made the announcement in a release carried by WFMZ.
The accepted candidate is a cereblon E3 ligase modulator, or CELMoD, designed for the partnership's molecular glue drug-discovery work. Evotec expects the candidate to enter a Phase 1 clinical trial in 2027. The partnership's first candidate entered a Phase 1 trial for advanced clear cell renal cell carcinoma in March 2026.
Partnership adds another clinical candidate
Evotec and Bristol Myers Squibb combine Evotec's multi-omics screening, AI-supported analytics and drug-design capabilities with Bristol Myers Squibb's CELMoD compound library. The collaboration began in 2018 with Celgene, which was later acquired by Bristol Myers Squibb, and was expanded in 2022.
For investors, the regulatory acceptance marks another development milestone for the partnered pipeline, but it is not a marketing authorization or evidence of clinical efficacy. The next stated step is the planned Phase 1 trial, where safety, tolerability and potential therapeutic activity will be assessed.
Evotec stock traded at 2.78 euros on Lang & Schwarz at 11:52 CET on Thursday, November 19, 2026, 1.09 percent above the Xetra close of Wednesday, November 18, 2026, at 2.75 euros.
Evotec stock details
- Company: Evotec SE
- ISIN: DE0005664809
- Ticker: EVT
- Home exchange: Frankfurt Stock Exchange
- Xetra close: 2.75 euros on November 18, 2026, according to ARIVA
European equities remained the broader market setting, with the DAX providing the relevant domestic benchmark.
